Clinical trial · Interventional
Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis
Advanced MRI for Intracranial Metastasis Treated With Stereotactic Radiosurgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial studies the different types of investigational imaging techniques called sequences during magnetic resonance imaging (MRI) of the head before and after radiation therapy in patients with cancer that has spread to the brain (intracranial metastases). This clinical trial also compares these new techniques with standard MRI imaging to see if sequences provide better images. Diagnostic procedures, such as MRI, may help find and diagnose solid organ cancer and find out how far the disease has spread.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Solid Neoplasm | Malignant Solid Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Advanced Magnetic Resonance Imaging | Procedure | — | UNRESOLVED |
| Conventional Magnetic Resonance Imaging | Procedure | — | UNRESOLVED |
| Gadolinium-Chelate | Drug | — | UNRESOLVED |
| Iopamidol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Diagnostic (advanced MRI)
- description
- Patients undergo conventional and advanced MRI over 60 minutes within 14 days before the start of scheduled brain radiation treatment. Patients then undergo 7 additional MRI over 60 minutes each between 4-16 weeks apart. Patients may receive gadolinium and/or iopamidol during MRI scans.
- interventionNames
- Procedure: Advanced Magnetic Resonance Imaging
- Procedure: Conventional Magnetic Resonance Imaging
- Drug: Gadolinium-Chelate
- Drug: Iopamidol
Primary outcomes (1)
- measure
- Contrast to Noise Ratio
- timeFrame
- Participants enrolled in the study were followed for variable amounts of times (up to 2 years and 4 months) from the date of their enrollment and baseline imaging
- description
- Contrast enhancement compared to baseline and normalized to background noise
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * An adult patient with pathology-proven solid organ cancer * MRI of the brain with contrast, positive for at least one intra-axial metastatic lesion greater than 5 mm * Planned treatment with stereotactic radiation Exclusion Criteria: * Contraindication to MR imaging * Known allergy to gadolinium-based contrast agents * Renal failure as defined by a glomerular filtration rate (GFR) less than 30 or the use of hemodialysis * Pregnant * Patients less than 18 years of age will be excluded
References
Publications (0)
Data not yet available